Search

Aim: Duchenne Muscular Dystrophy (DMD) results in a deficiency of dystrophin expression in patient muscle fibers, leading to progressive muscle degeneration. Treatment of DMD has undertaken current transformation with the advancement of novel gene therapy and molecular biology techniques, which are secure, well-tolerated, and effective therapeutic approaches. Introduction: DMD gene therapies have mainly focused on young DMD patients as in vivo animal model trials have been performed in 0–1-month DMD mice. However, it has not yet been answered how micro-dystrophin encoding lentiviral treatment affects Dystrophin expression and DMD symptoms in 10-month mdx mice. Methods: We planned to integrate the micro-Dystrophin gene sequence into the muscle cells by viral transfer, using micro-Dystrophin-encoding lentivirus to reduce the dystrophic pathology in late-stage dmd mice. The histopathological and physiological-functional regeneration activities of the lentiviral-micro-Dystrophin gene therapy methods were compared, along with changes in temporal Dystrophin expression and their functionality, toxicity, and gene expression level. method: We planned to integrate the micro-Dystrophin gene sequence into the muscle cells by viral transfer, using micro-Dystrophin-encoding lentivirus to reduce the dystrophic pathology in late-stage dmd mice. The histopathological and physiological-functional regeneration activities of the lentiviral-micro-Dystrophin gene therapy methods were compared, along with changes in temporal Dystrophin expression and their functionality, toxicity, and gene expression level. Results: Here, we showed that the micro-dystrophin transgene transfers intramuscularly and intraperitoneally in late-stage dmd-mdx-4cv mice restored dystrophin expression in the skeletal and cardiac muscle (p Conclusion: Consequently, this study suggests that patients in the late stages of muscular dystrophy can benefit from lentiviral micro-dystrophin gene therapies to present an improvement in dystrophic muscle pathology. conclusion: Consequently, this study suggests that patients in the late stages of muscular dystrophy can benefit from the lentiviral micro-dystrophin gene therapies to present an improvement in dystrophic muscle pathology.

Background/Aim: In recent years, developing an embryo in in vitro conditions has been one of the most challenging and popular objectives in reproductive biology. In vitro models make observing the relationship between the two possible. Various cell culture and matrix models have been created to overcome embryonic disorganization during culturing. The primary aim of this study was to evaluate and compare the effects of fibrin, Ishikawa cell line, and a combination of both on the 3D multilayer uterine tissue cultures on a rat model, including a control group.Methods: This study was designed as a prospective controlled cohort study. The standard uterine culture model [CNT] (N: 3) constituted the control group. In addition, fibrin matrix-supported [FIB] (N: 3), Ishikawa cells-supported [ISH] (N: 3), and a combination of both [FIB+ISH] (N: 3) culture models were designated as the exposures. All models were cultured for 14 days. Afterwards, the optimal model was determined regarding glucose consumption, lactate production, endometrial thickness and gland count (primary outcomes) with semi-quantitative and statistical methods. Finally, the optimal model was implanted with blastocytes, and the survival duration was observed (secondary outcome).Results: There were significant differences between the groups in terms of glucose, lactate, endometrial thickness (millimeter), and the number of endometrial glands (P